| P50 | author | Ian Stratford | Q56529169 |
| | Adam Patterson | Q38324051 |
| P2093 | author name string | A L Harris | |
| | G E Adams | |
| | E C Chinje | |
| | H M Barham | |
| P2860 | cites work | The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay | Q43724328 |
| | Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity | Q46173146 |
| | Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors | Q48105624 |
| | The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233). | Q50772616 |
| | Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. | Q50886497 |
| | Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. | Q50904345 |
| | Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. | Q53397942 |
| | Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. | Q53470764 |
| | Preclinical studies of porfiromycin as an adjunct to radiotherapy. | Q54375648 |
| | Hypoxia-mediated nitro-heterocyclic drugs in the radio- and chemotherapy of cancer. An overview | Q39477090 |
| | Hypoxic cells as specific drug targets for chemotherapy | Q39602421 |
| | Tumor hypoxia: its impact on cancer therapy | Q39763935 |
| | Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. | Q40450092 |
| | The experimental development of bioreductive drugs and their role in cancer therapy. | Q40848141 |
| | Bioreductive drugs for cancer therapy: the search for tumor specificity | Q41033230 |
| | Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors | Q41213138 |
| | Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression | Q41473428 |
| | Reductive activation of mitomycin C by NADH:cytochrome b5 reductase. | Q41520687 |
| | Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. | Q41530059 |
| | EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models | Q41579896 |
| | Reductive metabolism of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) and the induction of unscheduled DNA synthesis in rat and human derived cell lines | Q41727099 |
| | Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice | Q42088846 |
| | Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix | Q42619534 |
| | A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding | Q25938984 |
| | SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells | Q28303921 |
| | Nicotinamide, Fluosol DA and Carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo | Q33332643 |
| | A human cell line from a pleural effusion derived from a breast carcinoma | Q34207627 |
| | Bioreductive mechanisms | Q35901706 |
| | Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies | Q35975685 |
| | Regulation of cytochrome P450 gene expression in human colon and breast tumour xenografts | Q35976231 |
| | SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours | Q35976983 |
| | The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation | Q35982394 |
| | SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures | Q35983232 |
| | Expression of cytochrome P450IA in breast cancer | Q35984695 |
| | Hypoxic fractions of human tumors xenografted into mice: a review | Q37856864 |
| | The maintenance of cytochrome P-450 in rat hepatocyte culture: some applications of liver cell cultures to the study of drug metabolism, toxicity and the induction of the P-450 system | Q37912936 |
| | Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic tumors in man | Q58212471 |
| | Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) | Q64390275 |
| | Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908) | Q67744025 |
| | The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase? | Q68025801 |
| | The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-l,2,4-benzotriazine-l ,4-dioxide (SR 4233, WIN 59075) by mouse liver | Q68232111 |
| | Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical | Q68254687 |
| | Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy | Q68327742 |
| | Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas | Q68596887 |
| | Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin | Q68795522 |
| | Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively ac | Q68898207 |
| | Potential bioreductive alkylating agents. 1. Benzoquinone derivatives | Q69386558 |
| | Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins | Q69580840 |
| | RSU 1069, a nitroimidazole containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions | Q69609437 |
| | Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements | Q70168020 |
| | Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro | Q70335218 |
| | Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075) | Q70630698 |
| | Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines | Q72464961 |
| | Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia | Q72770316 |
| | Protection against SR 4233 (Tirapazamine) aerobic cytotoxicity by the metal chelators desferrioxamine and tiron | Q72806698 |
| | Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone | Q72830573 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1144-1150 | |
| P577 | publication date | 1995-11-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). | |
| P478 | volume | 72 | |